E. Wehrle

Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST)

G. Demetri, H. Joensuu, C. Blanke, 2008 .

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

Martin C. Müller, J. Radich, R. Larson, 2010, Blood.

Is serum β2-microglobulin a tumor marker in gastrointestinal cancer?

E. Wehrle, F. A. Anderer, H. Staab, 1980 .

Clinical Trials and Observations

R. A. Larson, Martin C. Müller, J. Radich, 2022 .

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

J. Goldman, A. Hochhaus, I. Gathmann, 2005 .

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

G. Demetri, A. Racine, H. Joensuu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

G. Demetri, H. Joensuu, M. Heinrich, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) *

Martin C. Müller, J. Radich, R. Larson, 2010 .